Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module

Julie A Panepinto, J Paul Scott, Oluwakemi Badaki-Makun, Deepika S Darbari, Corrie E Chumpitazi, Gladstone E Airewele, Angela M Ellison, Kim Smith-Whitley, Prashant Mahajan, Sharada A Sarnaik, T Charles Casper, Larry J Cook, Julie Leonard, Monica L Hulbert, Elizabeth C Powell, Robert I Liem, Robert Hickey, Lakshmanan Krishnamurti, Cheryl A Hillery, David C Brousseau, Pediatric Emergency Care Applied Research Network (PECARN), Julie A Panepinto, J Paul Scott, Oluwakemi Badaki-Makun, Deepika S Darbari, Corrie E Chumpitazi, Gladstone E Airewele, Angela M Ellison, Kim Smith-Whitley, Prashant Mahajan, Sharada A Sarnaik, T Charles Casper, Larry J Cook, Julie Leonard, Monica L Hulbert, Elizabeth C Powell, Robert I Liem, Robert Hickey, Lakshmanan Krishnamurti, Cheryl A Hillery, David C Brousseau, Pediatric Emergency Care Applied Research Network (PECARN)

Abstract

Background: Detecting change in health status over time and ascertaining meaningful changes are critical elements when using health-related quality of life (HRQL) instruments to measure patient-centered outcomes. The PedsQL™ Sickle Cell Disease module, a disease specific HRQL instrument, has previously been shown to be valid and reliable. Our objectives were to determine the longitudinal validity of the PedsQL™ Sickle Cell Disease module and the change in HRQL that is meaningful to patients.

Methods: An ancillary study was conducted utilizing a multi-center prospective trial design. Children ages 4-21 years with sickle cell disease admitted to the hospital for an acute painful vaso-oclusive crisis were eligible. Children completed HRQL assessments at three time points (in the Emergency Department, one week post-discharge, and at return to baseline (One to three months post-discharge). The primary outcome was change in HRQL score. Both distribution (effect size, standard error of measurement (SEM)) and anchor (global change assessment) based methods were used to determine the longitudinal validity and meaningful change in HRQL. Changes in HRQL meaningful to patients were identified by anchoring the change scores to the patient's perception of global improvement in pain.

Results: Moderate effect sizes (0.20-0.80) were determined for all domains except the Communication I and Cognitive Fatigue domains. The value of 1 SEM varied from 3.8-14.6 across all domains. Over 50% of patients improved by at least 1 SEM in Total HRQL score. A HRQL change score of 7-10 in the pain domains represented minimal perceived improvement in HRQL and a HRQL change score of 18 or greater represented moderate to large improvement.

Conclusions: The PedsQL™ Sickle Cell Disease Module is responsive to changes in HRQL in patients experiencing acute painful vaso-occlusive crises. The study data establish longitudinal validity and meaningful change parameters for the PedsQL™ Sickle Cell Disease Module.

Trial registration: ClinicalTrials.gov (study identifier: NCT01197417 ). Date of registration: 08/30/2010.

Keywords: Acute pain crises; Longitudinal validity; Quality of life; Responsiveness; Sickle cell disease.

Figures

Fig. 1
Fig. 1
Cumulative Distribution Curve for the Child Self Report PedsQL™ Sickle Cell Disease Total Score
Fig. 2
Fig. 2
Cumulative Distribution Curve for the Child Self Report PedsQL™ Multidimensional Fatigue Scale Total Score
Fig. 3
Fig. 3
Cumulative Distribution Curve for the Child Self Report PedsQL™ Generic Core Total Score
Fig. 4
Fig. 4
Cumulative Distribution Curve for the Child Self Report PedsQL™ Sickle Cell Disease Pain Impact Score
Fig. 5
Fig. 5
Cumulative Distribution Curve for the Child Self Report PedsQL™ Sickle Cell Disease Pain and Hurt Score
Fig. 6
Fig. 6
Cumulative Distribution Curve for the Child Self Report PedsQL™ Sickle Cell Disease Pain Management Score

References

    1. Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr Blood Cancer. 2012;59(2):377–385. doi: 10.1002/pbc.24176.
    1. Panepinto JA, Torres S, Bendo CB, McCavit TL, Dinu B, Sherman-Bien S, et al. PedsQL sickle cell disease module: feasibility, reliability, and validity. Pediatr Blood Cancer. 2013;60(8):1338–1344. doi: 10.1002/pbc.24491.
    1. Brousseau DC, Scott JP, Badaki-Makun O, Darbari DS, Chumpitazi CE, Airewele GE, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015;126(14):1651–1657. doi: 10.1182/blood-2015-05-647107.
    1. Badaki-Makun O, Scott JP, Panepinto JA, Casper TC, Hillery CA, Dean JM, Brousseau DC, Pediatric Emergency Care Applied Research Network Magnesium in Sickle Cell Crisis Study G: Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial. Pediatr Blood Cancer 2014, 61(6):1049-1054.
    1. Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL in pediatric cancer: reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer. 2002;94(7):2090–2106. doi: 10.1002/cncr.10428.
    1. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70. doi: 10.1186/1477-7525-4-70.
    1. Cohen LaH M. Statistics for social scientists. London: Harper and Row; 1982.
    1. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999;37(5):469–478. doi: 10.1097/00005650-199905000-00006.
    1. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52(9):861–873. doi: 10.1016/S0895-4356(99)00071-2.
    1. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):171–184. doi: 10.1586/erp.11.9.
    1. Panepinto JA, O'Mahar KM, DeBaun MR, Rennie KM, Scott JP. Validity of the child health questionnaire for use in children with sickle cell disease. J Pediatr Hematol Oncol. 2004;26(9):574–578. doi: 10.1097/01.mph.0000136453.93704.2e.
    1. Panepinto JA, Pajewski NM, Foerster LM, Sabnis S, Hoffmann RG. Impact of family income and sickle cell disease on the health-related quality of life of children. Qual Life Res. 2009;18(1):5–13. doi: 10.1007/s11136-008-9412-8.
    1. FDA. Guidance for Industry: Patient-reported outcome measures: Use in medical product development to support labeling claims [].
    1. Cappelleri JC, Bushmakin AG. Interpretation of patient-reported outcomes. Stat Methods Med Res. 2014;23(5):460–483. doi: 10.1177/0962280213476377.
    1. Johnston BC, Ebrahim S, Carrasco-Labra A, Furukawa TA, Patrick DL, Crawford MW, et al. Minimally important difference estimates and methods: a protocol. BMJ Open. 2015;5(10) doi: 10.1136/bmjopen-2015-007953.
    1. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–109. doi: 10.1016/j.jclinepi.2007.03.012.
    1. Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of International Society for Quality of Life R Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. 2013;22(3):475–483. doi: 10.1007/s11136-012-0175-x.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa